Study #2020-0308
A Phase I Study of Cabozantinib and Pamiparib to Evaluate Triple of PARP, VEGFR and c-MET in Advanced Homologous Recombination Deficient Malignancies
MD Anderson Study Status
Not Accepting
Treatment Agent
Cabozantinib, Pamiparib
Description
This phase I trial finds the best dose and side effects of cabozantinib and pamiparib in treating patients with solid tumors that have spread to other places in the body (advanced) or does not respond to treatment (refractory). Cabozantinib and pamiparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm
Study phase:
Phase I
Physician name:
Siqing Fu
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-866-419-2881
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.